Education on the Treatment of Migraines

Clinical Resources & Education on Migraines

Migraine affects approximately 44 million people in the United States and one billion people globally. The personal, professional, and financial costs through lost productivity and quality of life are immense. Despite its prevalence and impact on individuals, families, and society, migraine is under-recognized, underdiagnosed, and undertreated.

Migraine Educational Material

Interviews with patients integrated into the educational activities uncovered chronic migraine episodes that sidelined careers, interrupted social engagements, and impacted individuals’ ability to function. Patients look to their health care providers to share information, insights, and experience as part of shared decision-making to find multimodal treatment strategies that will curtail the disability of migraine.

New agents targeting the calcitonin gene-related peptide (CGRP) pathway have shown great promise and have led to excitement within the migraine community. Our goal for the Migraine Digital Hub is to provide educational activities, clinical information, resources, and assessment  for the diagnosis and management of migraine. Our end goal is to improve the lives of individuals with migraine.

Individualizing Care in Migraine: From Prevention to Acute Management

Participate Now

This video is a replay of a plenary session from the 11th Annual Chair Summit Master Class for Neuroscience Professional Development held in Ft. Lauderdale, FL on February 7-9, 2019. Note: Credit is no longer available. 

Getting Ahead of Migraine: Integrating Preventive Strategies Into Migraine Care

Participate Now

Migraine is a debilitating condition with profound effects on individuals’ quality of life, accounting for five to nine million primary care visits each year. It is estimated that 38% of sufferers could benefit from preventative treatment, but few are currently using them nor are their healthcare providers discussing these options with them. Consequently, there is great interest in emerging data about calcitonin gene-related peptide (CGRP) agents as novel options for migraine prevention and the benefits they may provide to patients. Note: Credit is no longer available.

The International Classification of Headache Disorders, 3rd Edition


Read Now!

Charles A. The Pathophysiology of Migraine: Implications for Clinical Management. Lancet Neurol. 2018;17(2):174-182. (LINK)


Skljarevski V, et al. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol. 2018;75(2):187-193. (LINK)


Goadsby P, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123-2132. (LINK)


Silberstein SD, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017:377(22):2113-2122. (LINK)


Charles A. Migraine. N Engl J Med. 2017;377(6):553-561. (LINK)


Buse DC, et al. Impact of Migraine on the Family: Perspectives of People with Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc. 2016 Apr 25. [Epub ahead of print] (LINK)


Charles A, Hansen JM. Migraine Aura: New Ideas About Cause, Classification, and Clinical Significance. Curr Opin Neurol.2015;28(3):255-260. (LINK)

American Migraine Foundation – Website